Dr. Julie R. Brahmer

Dr. Julie R. Brahmer, MD, MSc, is a world-renowned thoracic oncologist specializing in lung cancer and immunotherapy. She serves as Professor of Oncology at Johns Hopkins University School of Medicine and Director of the Thoracic Oncology Program at Sidney Kimmel Comprehensive Cancer Center. Dr. Brahmer earned her medical degree from the University of Nebraska Medical Center, completed residency training in internal medicine at the University of Utah, and pursued fellowship training in medical oncology at Johns Hopkins. She also earned a Master of Science in Clinical Investigation from Johns Hopkins Bloomberg School of Public Health. She is board-certified in Internal Medicine and Medical Oncology.

A global leader in immuno-oncology, Dr. Brahmer played a pivotal role in the clinical development of immune checkpoint inhibitors, including the first anti–PD-1 and anti–PD-L1 therapies for lung cancer. Her research has redefined treatment standards for advanced non-small cell lung cancer and continues to focus on novel immunotherapy combinations, biomarkers of response, and toxicity management. She has authored numerous high-impact publications and has been instrumental in establishing immunotherapy as a cornerstone of thoracic oncology.

Beyond her scientific contributions, Dr. Brahmer is a dedicated mentor, training fellows and junior faculty in thoracic oncology research. She has served in leadership roles at ASCO and AACR, influencing national and international cancer policy and clinical trial design. Through her groundbreaking work, Dr. Julie Brahmer continues to shape the future of lung cancer therapy and immunotherapy worldwide.